Humoral and cellular immune functions are not compromised by the anticarcinogenic Bowman‐Birk inhibitor

Publisher Website
Google Scholar
Abstract
Previous studies have demonstrated that the soybean‐derived Bowman‐Birk protease inhibitor (BBI) is effective as a cancer chemopreventive agent in several animal model systems. Proteases represent a key component of several aspects of immune function; therefore the immune system is a primary target for potential toxicity. The present investigation examines the effect of dietary and intraperitoneally administered BBI on antibody response to keyhole limpet hemocyanin and delayed‐type hypersensitivity response to dinitrochlorobenzene. Primary antibody response was not altered by BBI treatment; however, an elevated secondary response was observed in animals receiving dietary BBI at two weeks of age. This effect was not observed at later time points. No change in delayed‐type hypersensitivity response was observed in any of the treatment groups.